RxDoctor Payments Data

Darren Gitelman, MD

Behavioral Neurology & Neuropsychiatry · Park Ridge, ILNPI 1164530804

Payments from drug & device makers

$3,446,628in general payments, 2019–2025

Across 251 payments — averaging $13,732 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.1M
  • Biogen$916K
  • Eisai Inc.$748K
  • AbbVie$381K
  • E.r. Squibb & Sons, L.L.C.$290K
  • Genentech, Inc.$27K
  • plus $6K from 4 others
$44,348in research payments, 2019–2025

Across 5 payments — averaging $8869.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$44K
  • AbbVie$124

What the payments were for

  • Consulting fees$45,97172%
  • Speaking & faculty fees$3,3905%
  • Travel & lodging$12,70120%
  • Food & beverage$1,2902%
  • Education$1050%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly31$1,078,158
Biogen17$915,984
Eisai Inc.86$748,458
AbbVie94$380,867
E.r. Squibb & Sons, L.L.C.8$290,282
Genentech, Inc.8$26,884
Lilly USA, LLC2$3,544
Novo Nordisk3$1,500
Merck1$800
Genentech USA, Inc.1$150

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few behavioral neurology & neuropsychiatry providers in Illinoisto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$89,760
Medicare patients
337
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Galantamine ErGalantamine Hbr271$23,516
RexultiBrexpiprazole13$22,613
Rivastigmine59$14,842
Memantine Hcl407$13,151
Donepezil Hcl357$4,806
Escitalopram Oxalate178$2,001
Quetiapine Fumarate76$1,358
Memantine Hcl ErMemantine Hcl19$1,209
Mirtazapine24$1,202
Carbidopa-LevodopaCarbidopa/Levodopa45$1,075
Venlafaxine Hcl ErVenlafaxine Hcl32$1,007
RivastigmineRivastigmine Tartrate14$906
Bupropion XlBupropion Hcl19$790
Trazodone Hcl76$569
Sertraline Hcl57$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$3,544$26627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Illinoison file to place this against a meaningful peer group, so we don't.

Other behavioral neurology & neuropsychiatry in Park Ridge

Where these figures come from

Is this you, or does something look wrong? →